Exploring Innovation and Excellence in Healthcare

 

The technology industry is most often associated with the term “innovation,” but startups and Silicon Valley execs aren’t the only ones rethinking how we do business. The Healthcare industry is constantly innovating and looking for new ways to be more efficient, safe, and excellent. “I Don’t Care,” talks about how healthcare organizations are making structural changes with guest Paul Aslin, a healthcare organization, transformation, and innovation expert.

After the economic downturn of 2008, Aslin found himself reassessing what he could do with his business experience that would produce meaningful work. He found the answer in healthcare. Today, Aslin works to help hospitals achieve organization excellence. He does so using the Baldridge criteria, an award that outlines seven categories of excellence: Leadership, strategy, customers, measurement analysis, knowledge management, workforce operations, and results.

Though the Baldridge criteria is intentionally vague, it helps organizations hone in on their mission and vision. Through clearly defined goals down to the director level, the criteria brings value to the organization. Aslin details how the submission-driven innovation program has helped spearhead various initiatives that lead to a more prosperous organization at both the employee and patient level.

Catch up on previous episodes of I Don’t Care with Kevin Stevenson!

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More